Biotech Values

[jq1234]

Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial

SAN DIEGO, Oct. 18, 2011 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-newsArticle&ID=1618101&highlight=